BiologicalDrug
Bococizumab clinical trials
Also written RN316 and PF-04950615.
- studies test it
- 19
- open now
- 0
- in phase 3
- 10
- first study started
- 2009
How studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2013 (5)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 5 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 3
- Phase 3
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 1
Often tested with
Tested in the same studies.
Hydroxymethylglutaryl-CoA Reductase Inhibitors (1)
Studies
Open first, then newest update. How each study uses bococizumab is read from its arms, and is right about nine times in ten.
Testing it · 19
- Bococizumab HIV Evaluation (B-HIVE) StudyTerminatedPhase 3University of California, San FranciscoNCT02524106Written as Bococizumab
- Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper ArmCompletedPhase 1PfizerNCT02043301Written as Bococizumab (PF-04950615; RN316)
- The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk SubjectsTerminatedPhase 3PfizerNCT01975389Written as bococizumab (PF-04950615)
- Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With HypercholesterolemiaCompletedPhase 1PfizerNCT01243151Written as PF-04950615 (RN316)
- Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsCompletedPhase 3PfizerNCT01968967Written as Bococizumab (PF-04950615; RN316)
- Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular EventsCompletedPhase 3PfizerNCT02100514Written as Bococizumab (PF-04950615; RN316)
- A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With HypercholesterolemiaCompletedPhase 1PfizerNCT01435382Written as PF-04950615 (RN316)
- The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk SubjectsTerminatedPhase 3PfizerNCT01975376Written as bococizumab (PF-04950615)
- Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With AtorvastatinCompletedPhase 1PfizerNCT01163851Written as 4 mg/kg
- Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or DyslipidemiaCompletedPhase 3PfizerNCT02458287Written as Bococizumab 150mg
- Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to StatinsCompletedPhase 3PfizerNCT02135029Written as Bococizumab (PF-04950615;RN316)
- Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A StatinCompletedPhase 2PfizerNCT01592240Written as 200mg PF-04950615 (RN316)
- Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia SubjectsWithdrawnPhase 3PfizerNCT02947334Written as Bococizumab
- A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of StatinsCompletedPhase 2PfizerNCT01350141Written as PF-04950615 (RN316)
- A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of StatinsCompletedPhase 2PfizerNCT01342211Written as PF-04950615 (RN316)
- A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial HypercholesterolemiaCompletedPhase 3PfizerNCT01968980Written as Bococizumab (PF-04950615;RN316)
- Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular EventsCompletedPhase 3PfizerNCT01968954Written as Bococizumab (PF-04950615;RN316)
- Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human HyaluronidaseTerminatedPhase 1PfizerNCT02667223Written as Cohort 1: bococizumab 150 mg + rHuPH20
- A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult SubjectsCompletedPhase 1PfizerNCT00991159Written as RN316
Given in every arm · 2 — bococizumab is usual care beside what is tested
- Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese SubjectsCompletedPhase 2PfizerNCT02055976Written as Bococizumab (PF-04950615;RN316)
- A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic SubjectsCompletedPhase 1PfizerNCT01720537Written as PF-04950615 Dose A
Codes
What other systems call bococizumab · ClinicalTrials.gg INT000246
- MeSH (NLM) C000598888bococizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 45M75JVK38BOCOCIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q19596152BococizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166723BococizumabOne source FDA
- DrugBank DB12456One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000598888 | bococizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 45M75JVK38 | BOCOCIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q19596152 | Bococizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166723 | Bococizumab | One source FDA |
| DrugBank | DB12456 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.